Immuron Limited

ASX:IMC ISIN:AU000000IMC7

Immuron Ltd ASX:IMCImmuron Limited (ASX:IMC) (OTCMKTS:IMROY) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan(R) for the prevention of travellers' diarrhoea, whilst its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. These products together with the Company's other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market.
 
For more information visit: Immuron Website

 
  

News

Immuron Limited (ASX:IMC) Significantly Rerated by European/US Analyst's Report

🕔2/15/2017 10:24:23 AM 5305

Immuron Limited (ASX:IMC) (OTCMKTS:IMROY) wishes to advise investors that European and US-based Life Sciences Research and Analyst firm Van Leeuwenhoeck Institute, has published an updated in-depth Research Report on the Company and its R&D programs.

Read Full Article

Immuron Limited (ASX:IMC) Announces First Patient Enrolled in Pediatric Fatty-Liver Phase II Trial

🕔2/7/2017 9:00:32 AM 4812

Immuron Limited (ASX:IMC) (OTCMKTS:IMROY), an Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products to target inflammatory-mediated diseases, today announced that Emory University has enrolled its first patient in Immuron's IMM-124E pediatric NAFLD Phase II trial.

Read Full Article

Immuron Limited (ASX:IMC) Announces First USA Orders for Travelan(R)

🕔4/20/2015 4:02:07 PM 6330

Australian biopharmaceutical company Immuron Limited (ASX:IMC) (OTCMKTS:IMROY), manufacturer of Travelan(R), is pleased to announce that it has secured first orders for its Travelan(R) product in the USA.

Read Full Article
###

4,071 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 2) (Last 30 Days: 26) (Since Published: 4071) 

Company Data

    Headquarters
  • Suite 10- 25 Chapman Street
    Blackburn North VIC 3130
    Australia
  • Telephone
  • +61-3-9824-5254 
  • Fax
  • +61-3-9822-7735 
  • Principal Sector
  • Health & Pharm General 
  • Principal Industry
  • Healthcare 
  • Homepage
  • www.immuron.com
  • E:
  • jerrykanellos@immuron.com

More News Results

  • 2024/07/18: Immuron CEO to present at Emerging Growth Conference*
  • 2024/07/16: Notification of cessation of securities - IMC*
  • 2024/07/15: Immuron Travelan record sales globally, Australia and USA*
  • 2024/07/09: Immuron CEO Steven Lydeamore presentation to Sharewise*
  • 2024/07/04: Immuron CEO Steven Lydeamore to present at Sharewise*
  • 2024/07/03: Immuron lodges Form F-3 and ATM Prospectus with U.S. SEC*
  • 2024/07/02: IMM-529 pre-IND FDA filing*
  • 2024/06/05: Initial Director's Interest Notice JJ*
  • 2024/06/05: Final Director's Interest Notice RA*
  • 2024/05/31: Board Changes*
*refer to company website

Research Report

Download Presentation

Social Media